161. Global Sociodemographic Disparities in Ischemic Heart Disease Mortality According to Sex, 1980 to 2021.
作者: Ahmed Sayed.;Erin D Michos.;Ann Marie Navar.;Salim S Virani.;LaPrincess C Brewer.;JoAnn E Manson.
来源: Circ Cardiovasc Qual Outcomes. 2025年e011648页
Mortality due to ischemic heart disease (IHD) has declined in countries with high socioeconomic development. Whether these declines extend to other settings, and whether socioeconomic development influences IHD mortality among men and women differently, is unknown.
162. Association of Rurality With Mortality After Congenital Heart Surgery.
作者: Yanxu Yang.;Yijian Huang.;Jessica H Knight.;Matthew E Oster.;Lazaros K Kochilas.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷6期e011708页
Disparities between metro and nonmetro areas exist in health outcomes. The effect of residing areas on mortality for patients with congenital heart disease remains unclear. We evaluated the relationship of residing areas with survival outcomes after congenital heart surgery (CHS).
163. Musclin Counteracts Skeletal Muscle Dysfunction and Exercise Intolerance in Heart Failure With Preserved Ejection Fraction.
作者: Eng Leng Saw.;Louis Dominic Werner.;Hannah L Cooper.;David R Pimental.;Payman Zamani.;Julio A Chirinos.;María Valero-Muñoz.;Flora Sam.
来源: Circ Heart Fail. 2025年18卷6期e012350页
Exercise intolerance is a hallmark of heart failure with preserved ejection fraction (HFpEF) and is characterized by skeletal muscle (SkM) dysfunction with impaired oxidative capacity. To maintain oxidative capacity, the SkM secretes myokines such as musclin, which has been shown to potentiate NP (natriuretic peptide) signaling and induce PGC-1α (peroxisome proliferator-activated receptor-γ coactivator-1 alpha) signaling. We sought to investigate the role of musclin in SkM dysfunction in HFpEF. For this study, we selected the oxidative-predominant SkM soleus in HFpEF mice and vastus lateralis from patients with HFpEF.
164. Left Atrial Reverse Remodeling in Patients Supported With Durable Left Ventricular Assist Devices and Clinical Implications.
作者: Christos P Kyriakopoulos.;Konstantinos Sideris.;Iosif Taleb.;Eleni Maneta.;Eleni Tseliou.;Jake Aadland.;Andrew S Baird.;Michael J Bonios.;Marisca Nelson.;Elizabeth Dranow.;Matthew L Goodwin.;Thomas C Hanff.;Spencer Carter.;Craig H Selzman.;Josef Stehlik.;Omar Wever-Pinzon.;Satvik Ramakrishna.;Ethan Tumarkin.;Stavros G Drakos.
来源: Circ Heart Fail. 2025年e012807页
The left atrium (LA) maintains a dynamic interaction with the left ventricular (LV). LA forward and reverse remodeling affect prognosis in patients with chronic heart failure. We examined LA reverse remodeling in patients supported with LV assist devices (LVADs) and investigated a potential impact on clinical outcomes.
165. Clinical Impact of Persistent Microvascular Obstruction in CMR After Reperfused STEMI.
作者: Felix Troger.;Mathias Pamminger.;Paulina Poskaite.;Martin Reindl.;Magdalena Holzknecht.;Ivan Lechner.;Christina Tiller.;Sebastian von der Emde.;Alex Kaser.;Fritz Oberhollenzer.;Matthias Schwab.;Benjamin Henninger.;Bernhard Metzler.;Sebastian J Reinstadler.;Agnes Mayr.
来源: Circ Cardiovasc Imaging. 2025年18卷6期e017645页
Microvascular injury in the course of acute ST-segment-elevation myocardial infarction (STEMI) has been identified as determinant of adverse outcomes and manifests as microvascular obstruction (MVO). MVO has long been regarded as a transient finding, vanishing within a few weeks after infarction. However, recent studies have shown that it may persist beyond the early phase, resulting in adverse remodeling. However, its clinical implications remain unclear. This study aims to evaluate the association of MVO persistence and major adverse cardiac events after STEMI.
166. Deep Learning-Derived Cardiac Chamber Volumes and Mass From PET/CT Attenuation Scans: Associations With Myocardial Flow Reserve and Heart Failure.
作者: Waseem Hijazi.;Aakash Shanbhag.;Robert J H Miller.;Paul B Kavanagh.;Aditya Killekar.;Mark Lemley.;Samuel Wopperer.;Stacey Knight.;Viet T Le.;Steve Mason.;Wanda Acampa.;Tom Rosamond.;Damini Dey.;Daniel S Berman.;Panithaya Chareonthaitawee.;Marcelo F Di Carli.;Piotr J Slomka.
来源: Circ Cardiovasc Imaging. 2025年e018188页
Computed tomography (CT) attenuation correction scans are an intrinsic part of positron emission tomography (PET) myocardial perfusion imaging using PET/CT, but anatomic information is rarely derived from these ultralow-dose CT scans. We aimed to assess the association between deep learning-derived cardiac chamber volumes (right atrial, right ventricular, left ventricular, and left atrial) and mass (left ventricular) from these scans with myocardial flow reserve and heart failure hospitalization.
167. Revisiting the Open Vein Hypothesis to Reduce the Postthrombotic Syndrome: Implications for Multidisciplinary Care and Research: A Scientific Statement From the American Heart Association.
作者: Wenzhu Li.;Suresh Vedantham.;Farouc A Jaffer.;Stavros K Kakkos.;Jean-Philippe Galanaud.;Paul P Dobesh.;Eri Fukaya.;Mary O Whipple.;Olamide Alabi.;Rachel P Rosovsky.;Peter K Henke.; .
来源: Circulation. 2025年151卷23期e1051-e1071页
The "open vein hypothesis" postulates that early thrombus clearance and restoration of venous blood flow may prevent postthrombotic syndrome after proximal deep vein thrombosis. Since its proposal several decades ago, new insights from basic and clinical studies have motivated a re-evaluation and refinement of this hypothesis. According to data from these studies, susceptibility to postthrombotic syndrome occurs as a result of differences in genetic composition, thrombophilic conditions, predilection to inflammation and fibrosis, endogenous fibrinolytic capability, timing of symptom presentation and treatment initiation, and efficacy of antithrombotic therapy. Although initial restoration of an open vein appears to be beneficial for selected patient groups, freedom from postthrombotic syndrome is more likely in the setting of long-term venous patency, reduced recurrent thrombotic episodes, and reduced perithrombotic (eg, vein wall and valve) inflammation. These underlying biological mechanisms need further elucidation, with a long-term goal of personalizing treatment by mapping the individuals' clinical presentation with their underlying risk factors and assessing time-dependent biological processes that occur as a clinical venous thrombosis resolves. This scientific statement (1) highlights historical fundamentals of the open vein hypothesis and then showcases new research insights into the pathophysiological factors driving postthrombotic syndrome; (2) discusses advantages and disadvantages of imaging modalities for deep vein thrombosis used in clinical practice, including the potential to depict thrombus chronicity and status of vein wall injury; (3) proposes measures to develop integrated multidisciplinary care for deep vein thrombosis focused on the reduction of postthrombotic syndrome; and (4) identifies priority areas and questions for further research.
168. METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy.
作者: Chunyan Wang.;Siman Shen.;Jiayi Kang.;Aya Sugai-Munson.;Xiao Xiao.;Yajing Zhang.;Junyuan Zhu.;Zipeng Liu.;Tina B McKay.;Oluwaseun Akeju.;Eric R Jonas.;Amrut V Ambarar.;Michael R Bristow.;Weifeng Yao.;Haobo Li.
来源: Circulation. 2025年
Exercise improves functional outcomes in patients with diabetic cardiomyopathy (DiaCM). The molecular mechanism underlying cardiac benefits of exercise in DiaCM remains incompletely understood. N6-methyladenosine (m6A) is the most common form of messenger RNA modification in eukaryotes and has been implicated in cardiac development and disease. However, the role of m6A in DiaCM and in the mitigating effects of exercise on this disease are unclear.
169. Exploring the Hidden Side of Ventricular Arrhythmias in Elite Athletes With Structural Normal Hearts.
作者: Giuseppe Di Gioia.;Maria Rosaria Squeo.;Cosimo Damiano Daniello.;Armando Ferrera.;Viviana Maestrini.;Sara Monosilio.;Federica Mango.;Giulia Paoletti.;Andrea Serdoz.;Antonio Pelliccia.
来源: Circ Arrhythm Electrophysiol. 2025年18卷6期e013807页 170. Dusp14-Mediated Dephosphorylation of MLKL Protects Against Cardiomyocyte Necroptosis in Hypothyroidism-Induced Heart Failure.
作者: Yitian Zheng.;Yueyue Cao.;Wenyao Wang.;Yicheng Tong.;Shuaixing Wang.;Chen Li.;Mingming Zhao.;Yao Song.;Yuan-Geng-Shuo Wang.;Jiating Qi.;Chao Wu.;Jie Yang.;Jilin Zheng.;Jun Gao.;Jingjia Wang.;Qing Yang.;Gang Liu.;Jiajun Zhao.;Yan Zhang.;Han Xiao.;You-Yi Zhang.;Yi-Da Tang.
来源: Circulation. 2025年
Hypothyroidism leads to multiple organ dysfunction, with the heart the most affected. However, the pathologic mechanism of hypothyroidism-induced heart failure remains to be completely elucidated. Thyroid hormone replacement therapy enhances myocardium systolic function but increases the occurrence of arrythmias. There is an urgent need to explore these mechanisms in detail and to discover and develop drugs that can target and manage heart failure in patients with hypothyroidism.
171. Impact of Natriuretic Peptide and Prior Hospitalization in Patients With Severe Mitral Regurgitation: COAPT Trial.
作者: Sachin S Goel.;Ashrith Guha.;JoAnn Lindenfeld.;William T Abraham.;Saibal Kar.;Samir R Kapadia.;Stephen H Little.;D Scott Lim.;Michael J Reardon.;Neal S Kleiman.;Janani Aiyer.;Lak Kotinkaduwa.;Michael Mack.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2025年e015192页
The clinical significance of elevated baseline natriuretic peptide level and prior heart failure hospitalization (HFH) within the prior year in mitral transcatheter edge-to-edge repair outcomes is unclear. This analysis examined the impact of BNP (B-type natriuretic peptide) or N-terminal prohormone BNP NT-proBNP (N-terminal pro-B-type natriuretic peptide) and prior HFH on outcomes in patients with severe secondary mitral regurgitation.
172. Correction to: Sedentary Behavior and Light-intensity Physical Activity During Pregnancy and Cardiovascular Health: A Science Advisory From the American Heart Association.
作者: Kara M Whitaker.;Bethany Barone Gibbs.;Marie-France Hivert.;Nour Makarem.;Elizabeth Moxley.;Jason Vaught.;Kelly R Evenson.; .
来源: Circulation. 2025年151卷19期e1000页 173. Correction to: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM.
作者: Milind Y Desai.;Kathy Wolski.;Anjali Owens.;Jeffrey B Geske.;Sara Saberi.;Andrew Wang.;Mark Sherrid.;Paul C Cremer.;Neal K Lakdawala.;Albree Tower-Rader.;David Fermin.;Srihari S Naidu.;Nicholas G Smedira.;Hartzell Schaff.;Zhiqun Gong.;Lana Mudarris.;Kathy Lampl.;Amy J Sehnert.;Steven E Nissen.; .
来源: Circulation. 2025年151卷19期e1001页 177. Response by Reitan et al to Letter Regarding Article, "Excess Mortality and Loss of Life Expectancy After Myocardial Infarction: A Registry-Based Matched Cohort Study".
作者: Christian Reitan.;Pontus Andell.;Robin Hofmann.;Tomas Jernberg.
来源: Circulation. 2025年151卷19期e988-e989页 178. The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4.
作者: Naveed Sattar.;Govinda J Weerakkody.;Darren K McGuire.;Mikhail N Kosiborod.;Matthew M Y Lee.;Paul Welsh.;Ewan R Pearson.;Russell J Wiese.;Kevin Duffin.;Jonathan Wilson.;Noemi Pavo.;Martin Hülsmann.;Imre Pavo.
来源: Circulation. 2025年151卷19期1430-1432页 179. Pressure-Derived Indices in the Left Main Coronary Artery: Insights From Comprehensive In Vivo Hemodynamic Studies of Diseased and Unobstructed Vessels.
作者: Ozan M Demir.;Aish Sinha.;Haseeb Rahman.;Matthew Ryan.;Kevin O'Gallagher.;Howard Ellis.;Matthew Li Kam Wa.;Smriti Saraf.;Khaled Alfakih.;Ian Webb.;Narbeh Melikian.;Kalpa De Silva.;Amedeo Chiribiri.;Sven Plein.;Divaka Perera.
来源: Circ Cardiovasc Interv. 2025年e015320页
Pressure-based physiological evaluation of coronary artery disease is well established, but its application is limited in left main coronary artery (LMCA) disease. Our aim was to investigate whether pressure-based indices are comparable in the left anterior descending (LAD) and left circumflex artery (LCx) branches of the LMCA, and if discordance is due to differences in microvascular function in these territories.
180. Get With the Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead.
作者: Amber B Tang.;Sabra C Lewsey.;Clyde W Yancy.;Paul A Heidenreich.;Stephen J Greene.;Larry A Allen.;Mariell Jessup.;Michele Bolles.;Christine Rutan.;Natalie Navar.;Kathie Thomas.;Gregg C Fonarow.
来源: Circ Heart Fail. 2025年e012936页
The Get With the Guidelines-Heart Failure program was developed in 2005 with the goal of bringing evidence-based guidelines in heart failure management into widespread clinical practice. The program includes workshops, webinars, tool kits, chart abstraction, performance benchmarking, and achievement awards to drive quality improvement at participating hospitals. Two decades after its inception, the program has grown to include over 600 participating institutions across the United States. Linking registry data to Centers for Medicare and Medicaid Services claims has also allowed for the evaluation of longitudinal outcomes. Get With the Guidelines-Heart Failure has helped improve the quality of care for patients and has contributed substantially to the understanding of clinical science and optimal management of heart failure. This narrative review provides an overview of the indelible impact of the Get With the Guidelines-Heart Failure program on quality heart failure care over the past 20 years and highlights future challenges and directions.
|